Table 3.
Outcome | Model 1a |
Model 2b |
Model 3c |
Model 4d |
||||
---|---|---|---|---|---|---|---|---|
Fold change (95% CI) | P | Fold change (95% CI) | P | Fold change (95% CI) | P | Fold change (95% CI) | P | |
FGF21 | 0.56 (0.32–0.98) | 0.04 | 0.48 (0.26–0.91) | 0.03 | 0.50 (0.26–0.95) | 0.04 | 0.54 (0.30–0.96) | 0.04 |
Values in bold denote P < 0.05.
For each outcome, the fold changes of outcome at high NASH activity with respect to low activity were reported.
Model 1 unadjusted.
Model 2 adjusts for age, gender, and BMI.
Model 3 adjusts for age, gender, BMI, and GFR.
Model 4 adjusts for age, gender, BMI, GFR, and HOMA-IR.
FGF, fibroblast growth factor; FGF21, fibroblast growth factor 21.